Abstract
Background: Comparative effectiveness of 7 glucagon-like peptide 1 (GLP-1) agents on weight loss (WL) in obesity is unknown. Methods: Study Design: Systematic review, network meta-analysis (NMA) Data Sources: MEDLINE, EMBASE, Scopus, Cochrane Central and clinical trial registries, from inception to March 2, 2021 Prespecified Criteria for Study Inclusion: Randomized clinical trials (RCTs) of >12 weeks’ duration. Data Appraisal and Extraction: Two investigators independently, using published reports. Main Outcomes and Statistical Methods: WL over placebo (WLOP) and adverse events (AEs) among GLP-1 agents using random-effects NMA (frequentist approach); relative ranking using surface under the cumulative ranking (SUCRA) method and certainty of evidence using GRADE. Registration: None Findings: Data Synthesis: 64 RCTs (2004-2021) had 27018 patients (medians of age, 55.1y; 57.4% women; baseline weight 94.8kg and BMI 33.0kg/m2; trial duration 26 weeks). Direct meta-analysis showed significant WLOP with: -1.44kg (95% CI, -2.14 to ‑0.74) with dulaglutide ≥1.5 mg; -1.82kg (‑2.42 to ‑1.23) with exenatide IR; -2.20kg (-4.31 to -0.08) with exenatide ER; -3.20kg (-6.53 to 0.15) with efpeglenatide; -2.72kg (‑3.35 to -2.09) with liraglutide ≤1.8mg; -4.49kg (-5.26 to -3.72) with liraglutide >1.8mg; ‑0.62kg (-1.22 to -0.02) with lixisenatide; ‑4.33kg (-5.71 to -3.00) with semaglutide SQ 1.8mg (SUCRAs 100, 86.1, 82.8 respectively). Highest SUCRAs for discontinuation due to AEs were with taspoglutide and liraglutide >1.8mg.Risk of bias was high or unclear for random sequence generation (29.7%), allocation concealment (26.6%), and incomplete outcome data (26.6%). Heterogeneity (I 2 >50%) in WL and AEs reflected magnitude, not direction of effect. Interpretation: Semaglutide (SQ, oral) and liraglutide (SQ) were the most efficacious GLP-1 agents to induce WL during > 12 weeks’ treatment. Funding: NIH R01-DK67071 (Camilleri) Declaration of Interest: Dr. Michael Camilleri serves on an advisory board for Phenomix Sciences regarding the company’s development of a test to predict weight loss response to obesity therapy, and he is a stockholder in the company. Phenomix Sciences has obtained an exclusive license to Dr. Michael Camilleri’s and Dr. Andres Acosta’s biomarker technology, submitted patent, and know-how to develop a biomarker to predict response to obesity pharmacotherapy. Dr. Camilleri also serves as a consultant to Kallyope for the company’s development program regarding obesity (the consulting fee is paid to his employer, Mayo Clinic). All other authors have nothing to declare.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.